Renuvion Safely and Effectively Treats Lax Skin in Trial
In a Phase II study, the Renuvion device improved the appearance of lax skin in 82.5% of subjects after 6 months.
In a Phase II study, the Renuvion device improved the appearance of lax skin in 82.5% of subjects after 6 months.
The platform integrates fat removal, closed-loop contouring, tissue contraction, and electrosurgical capabilities.
A noninvasive molecular test identifies patients more likely to respond to JAK inhibitors versus Th2-targeted therapies, potentially accelerating clearance and reducing treatment switches.